Reporter Gene Assay Market - Growth, Trends, and Forecasts (2023 - 2028)

The reporter gene assay market is projected to register a CAGR of 10.1% during the forecast period (2022-2027).

Amidst COVID-19, the reporter gene assay market is expected to grow owing to the rising cases of COVID-19 among people across the globe and the rising demand for vaccines and treatment drugs. The increase in the need for the development of vaccines for COVID-19 infected patients and the diagnosis of people is projected to create lucrative opportunities for the reporter gene assay market. Also, the increasing research on the COVID-19 virus to study the nucleic acid structure to produce suitable vaccine candidates has led to a surge in product approvals and launches. For instance, in August 2021, Creative Diagnostics launched a variety of lentiviral SARS-CoV-2 pseudoviruses from a wide range of coronavirus species. Different vectors can be used to express different reporters such as EGFP or luciferase, allowing the monitoring of viral entry into host cells by a variety of means. Such launches are expected to propel the research and development related to COVID-19 and, thus, COVID-19 is expected to have a significant impact on the growth of the market.

Moreover, the growing preference for cell-based assays is one of the major driving factors for the growth of the reporter gene assay market. This is due to the increasing usage of reported gene assays in life science research and biomanufacturing. The reporter gene assays are a crucial experimental tool to study the biochemistry and physiology of both healthy and diseased cells. Thus, the reporter gene assays gained much attention in studying emerging infectious viruses and developing drug therapies. Additionally, the increasing prevalence of chronic genetic disorders and infectious diseases among the population has led to increased demand for reporter gene assays owing to the cell-based applications in drug discovery. According to a World Health Organization report in 2022, chronic diseases such as cancer are one of the leading causes of death worldwide, accounting for nearly one in six deaths in 2020. The National Human Genome Research Institute report published in January 2020 stated that more than 6,800 rare diseases affect an estimated 25 to 30 million Americans. Therefore, the increasing incidences of rare and genetic disorders coupled with increasing demand for early diagnosis and effective treatment processes are expected to boost the growth of the market.

Additionally, the strategic initiatives undertaken by the market players are also expected to propel the growth of the market. For instance, in December 2021, Novartis acquired all share capital of the United Kingdom-based ocular gene therapy company Gyroscope therapeutics. This acquisition helped the company, Novartis, extend its portfolio into gene therapy.

Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period. However, the high cost of cell-based research may hinder the growth of the market.

Reporter Gene Assay Market Trends

The Assay Kits Segment is Expected to Hold a Major Market Share in the Reporter Gene Assay Market

The assay kits segment is expected to register significant revenue over the forecast period. The sudden outbreak of COVID-19 has increased the demand for reporter gene assays owing to their efficiency in studying the gene expression of the unknown virus to produce suitable vaccination.

The assay kits mostly used are fluorescent protein-related assay kits, secreted alkaline phosphate(SEAP) assay kits, luciferase assay kits, beta-galactosidase assay kits, and others. This is attributed to their increased usage in expression studies and signaling pathway analysis during gene transcription or translation levels. Also, the extensive usage of assays enables precise signal measurement, maintaining the consistency of the outcomes. In addition, they are convenient, fast, sensitive, and display a broadly linear pattern for detection. Moreover, the rising focus of researchers on establishing high-throughput assays of beta-galactosidase for reporter systems based on bacterial cells contributes to the fastest growth rate of the assay kit segments. This huge surge in demand for the assay kits segment is expected to propel the market's growth.

The launch of assay kits by market players is also propelling the growth of the segment. For instance, in June 2021, QIAGEN launched the QIAprep& amp; CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence.

Thus, owing to the abovementioned factors, the market segment is expected to propel the growth of the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period.

The North American region is likely to dominate the global market owing to the technological innovations in the diagnostic and reporter gene assay products used for disease testing. The region will retain its dominant position over the forecast years on account of investments by biotechnology companies and health care facilities to accelerate the development of gene therapies.

The growing investment by biotechnological and pharmaceutical companies in establishing facilities dedicated to research and manufacturing of gene therapy and related genetic products also drives the growth of the market. For instance, in December 2020, Taysha Gene Therapies, Inc. entered into a lease agreement to occupy and configure an approximately 187,000-square-foot commercial-scale current Good Manufacturing Practices (cGMP) manufacturing facility in Durham, North Carolina for preclinical, clinical, and commercial production of its gene therapy pipeline. Additionally, in December 2021, Pfizer Inc. reported the opening of a new, state-of-the-art clinical manufacturing facility in Durham, North Carolina. The facility expands Pfizer's end-to-end capabilities in gene therapy and builds on the company's existing footprint in North Carolina. The Durham facility is part of a USD 800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer's continued investment in gene therapy research, development, and manufacturing.

In addition, the launch of products such as assay kits in the region is also propelling the growth of the market. For instance, in November 2021, Asuragen, Inc., a Bio-Techne brand, launched a new kit to detect pathogenic variants in the CFTR gene, namely the AmplideX PCR/CE CFTR kit, intended for research use only. It provides broader coverage of the diverse United States population than any other commercially available, targeted CFTR testing assay. Such products, specifically targeting the United States population, are also propelling the growth of the market.

Thus, owing to the abovementioned factors, the market in the North American region is expected to show growth over the forecast period.

Reporter Gene Assay Market Competitor Analysis

The Reporter Gene Assay Market is competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some companies currently dominating the market are Thermo Fisher Scientific, Puritan Medical Products, Trinity Biotech, Medical Wire & Equipment, Vircell, Quidel Corporation, BD, Titan Biotech Limited, Copan Diagnostics, EKF diagnostics, Hardy Diagnostics, Pretium Packaging, and others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support